SAVARA: FDA's review of SAVARA's application for moxestine bioproduct licensing is ongoing; no revised date of action has been provided.

Zhitongcaijing · 21h ago
SAVARA: FDA's review of SAVARA's application for moxestine bioproduct licensing is ongoing; no revised date of action has been provided.